Skip to main content

Table 2 Investigator assessed efficacy endpoints in arm A and arm B

From: A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)

Endpoint Arm A Arm B   
  Median (95% CI) Median (95% CI) HR P value
Progression-free survival (months) 6.6 (5.1–9.0) 5.6 (3.8–6.5) 1.80 0.041
Overall survival (months) 20.7 (16.4–26.7) 12.1 (5.8–20.4) 2.01 0.018
Time to Progression (months) 6.6 (5.1–9.0) 5.3 (3.8–6.5) 1.98 0.030
Time to next treatment (months) 7.4 (6.1–10.4) 7.0 (5.8–10.3) 1.38 0.334
  n(%);(95% CI) n(%);(95% CI)   P value
Clinical control rate 28 (93.3) (77.6–99.2) 21 (70.0) (52.0–83.5)   0.020
Overall response rate 13 (43.3) (27.4–60.8) 12 (40) (24.6–57.7)   0.793